Exhibit 99.1 FOR IMMEDIATE RELEASE INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA HEALTHCARE REPORTS SECOND QUARTER 2025 RESULTS RAISES 2025 GUIDANCE Nashville, Tenn., July 25, 2025 – HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the second quarter ended June 30, 2025. Key second quarter metrics (all percentage changes compare 2Q 2025 to 2Q 2024 unless otherwise noted): "We are pleased to report strong financial results for ...

Group 1 - HCA Healthcare is set to release its Q2 earnings results on July 25, with expected earnings of $6.32 per share, an increase from $5.5 per share in the same period last year [1] - The company is projected to report quarterly revenue of $18.5 billion, up from $17.49 billion a year earlier [1] - HCA Healthcare appointed John W. Chidsey, III as a new Independent Director on July 11 [1] Group 2 - HCA Healthcare shares fell by 3.3%, closing at $341.48 [2] - Analysts have provided various ratings and price targets for HCA stock, with Truist Securities maintaining a Buy rating and raising the price target from $390 to $415 [7] - B of A Securities downgraded the stock from Buy to Neutral while increasing the price target from $394 to $410 [7] - JP Morgan assumed a Neutral rating with a price target of $380 [7] - Keybanc initiated coverage with an Overweight rating and a price target of $475 [7]

Core Viewpoint - Analysts forecast HCA Healthcare will report quarterly earnings of $6.14 per share, reflecting an 11.6% year-over-year increase, with revenues expected to reach $18.46 billion, a 5.5% increase compared to the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised downward by 0.3% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Analysts estimate 'Revenues- Other' to be $1.02 billion, representing a year-over-year increase of 19.6% [4]. - 'Revenues- Medicare' is projected at $2.82 billion, a 7.6% increase from the previous year, while 'Revenues- Managed Medicare' is expected to be $3.00 billion, reflecting a 3.1% increase [5]. - 'Revenues- International (Managed Care & Insurers)' is anticipated to reach $432.32 million, indicating a 3.9% year-over-year change [5]. Key Metrics - 'Revenue per Equivalent Admission' is expected to be $18,084.34, up from $17,583.00 in the same quarter last year [6]. - Analysts predict 'Equivalent Admissions' to be 1.02 billion, compared to 994.84 million a year ago, and 'Admissions' at 573.97 million, up from 554.46 million [6]. - 'Patient Days' are forecasted to reach 2,786 days, an increase from 2,663 days in the same quarter last year [7]. - The estimated 'Inpatient Revenue per Admission' is $19,563.87, compared to $18,814.00 in the same quarter last year [8]. Market Performance - Over the past month, HCA shares have returned -3.7%, contrasting with the S&P 500 composite's +5.9% change [8].

Core Insights - HCA Healthcare, Inc. is expected to report second-quarter 2025 results on July 25, with earnings estimated at $6.14 per share and revenues at $18.46 billion [1] - The earnings estimate reflects an 11.6% increase year-over-year, while revenue is projected to grow by 5.5% [2] - For the full year 2025, revenue is estimated at $74.6 billion, indicating a 5.7% year-over-year rise, and EPS is projected at $25.26, a 15% increase [3] Earnings Performance - HCA has a history of exceeding earnings estimates, achieving this in the last four quarters with an average surprise of 7.1% [3] - However, current indicators suggest uncertainty regarding an earnings beat for the upcoming quarter, with an Earnings ESP of -8.77% and a Zacks Rank of 3 [4] Operational Metrics - The consensus estimate for equivalent admissions indicates a 2.9% year-over-year growth, with revenue per equivalent admission also expected to rise by 2.9% [5] - Equivalent patient days are projected to grow by 4.3% year-over-year, and occupancy is expected to increase to 73.1% from 71.9% a year ago [5] Cost and Surgery Trends - Total operating expenses are anticipated to rise by 6.5% year-over-year, driven by higher salaries, benefits, and supply costs, with supply costs expected to increase by 5.3% [8] - A decline of 2.2% in outpatient surgery cases is projected, along with a 1.4% decrease in the average length of stay [9]

Industry Overview - The Zacks Medical-Hospital industry includes for-profit hospital companies providing various healthcare services, such as acute care, rehabilitation, and psychiatric services [3] - Revenue generation is influenced by inpatient occupancy levels, medical services ordered by physicians, and outpatient procedure volumes [3] - Payments for services come from government programs like Medicare and Medicaid, managed care plans, private insurers, and directly from patients [3] Key Trends - Rising patient demand is noted, particularly with an increase in elective procedures, while the 65+ population is projected to grow from 17.3% in 2022 to 22.8% by 2050 [4] - Health spending is expected to reach $5.3 trillion by 2025, but there is a shift from inpatient to outpatient and home-based services, leading to underused hospital beds [4] - Labor shortages, higher wages, and supply chain disruptions are squeezing hospital margins, prompting providers to adopt automation and refine staffing models [5] - Hospitals are investing in AI, automation, and real-time analytics to improve care delivery and operational efficiency [6] Consolidation and M&A Activity - Consolidation through mergers and acquisitions is a key strategy for hospitals to scale operations and increase market share in a fragmented market [2] - Post-pandemic, M&A activity has rebounded as hospitals seek efficiency and financial resilience, driven by economic recovery and regulatory clarity [7] Financial Performance and Outlook - The Zacks Medical-Hospital industry currently holds a Zacks Industry Rank of 181, placing it in the bottom 26% of nearly 250 Zacks industries, indicating challenging near-term prospects [8] - Aggregate earnings estimates for the industry have decreased by 0.2% since February-end, reflecting a negative outlook for earnings growth [9] - The industry has gained 4.2% over the past year, underperforming the S&P 500's 13.1% but outperforming the broader Medical sector's decline of 17.6% [11] Current Valuation - The industry trades at a trailing 12-month EV/EBITDA ratio of 7.84X, compared to the S&P 500's 17.79X and the sector's 9.72X [14] - Over the past five years, the industry's EV/EBITDA ratio has ranged from a high of 9.55X to a low of 6.45X, with a median of 8.03X [14] Notable Companies - **HCA Healthcare**: Positioned to benefit from rising patient volumes, with a projected 15% year-over-year EPS growth for 2025 and a 5.7% revenue increase [18] - **Tenet Healthcare Corporation**: Strong revenue growth driven by its Ambulatory Care and Hospital segments, with projected revenue of $20.9 billion for 2025 [22] - **Universal Health Services**: Growth supported by rising patient days and network expansion, with projected EPS growth of 17% for 2025 [26] - **Community Health Systems**: Benefiting from higher occupancy rates and a growing telehealth focus, with projected EPS growth of 69.9% for 2025 [31]

Group 1 - Bank of America downgraded Centene's rating from "Neutral" to "Underperform" with a target price cut from $52 to $30 due to concerns over the impact of the recently signed "Big Beautiful Law" by President Trump [1] - The downgrade is attributed to expected slow growth in the Medicaid market and the potential expiration of exchange subsidies this year, which poses dual pressures on Centene [1] - Analyst Joanna Gajuk indicated that significant changes in risk pools are expected to lead to more downside than upside in exchange pricing risks by 2026, with adverse effects on Medicaid enrollment starting to manifest from 2027 [1] Group 2 - HCA Healthcare's rating was downgraded from "Buy" to "Neutral," with a slight target price adjustment from $410 to $394, as funding cuts from the ACA and Medicaid are anticipated to create headwinds [1] - The decline in insured individuals may result in slower growth in hospital visits and increased bad debt, although HCA is expected to be less affected than peers due to its scale advantages [2] - The law significantly raises the likelihood of the expiration of enhanced exchange subsidies, which is expected to create additional resistance in 2026 [2]

Core Viewpoint - The Las Vegas Global Economic Alliance (LVGEA) has appointed three new members to its Board of Directors, enhancing its capacity to drive economic growth in Southern Nevada [1][2]. Group 1: New Board Members - Jackie Van Blaricum, President of HCA Healthcare Far West Division, has nearly 24 years of experience at HCA and is recognized for her leadership and commitment to community health [2][3][4]. - Marc Badain, President of MLB Athletics, is leading the franchise's relocation to Las Vegas and has extensive experience in major league sports, including overseeing the Raiders' relocation [5][6][7]. - Dr. Chris Heavey, Interim President of UNLV, has over 30 years of experience in education and research, focusing on aligning education with regional workforce needs [7][8][9]. Group 2: Contributions to Economic Growth - The new board members bring expertise from healthcare, sports, and education, which are crucial sectors for the economic development of Southern Nevada [2][7]. - Their collective experience and commitment are expected to foster community-driven growth and enhance the region's appeal as a place to live and work [2][7][10]. - LVGEA aims to leverage these leaders' insights to strengthen local healthcare, support innovation, and create new opportunities for residents [4][10].

Economic Outlook - The probability of a U.S. recession in 2025 is decreasing from a peak of 60% to below 50% due to the Trump administration easing aggressive tariff policies, which has allowed the S&P 500 to recover from a correction in March [1] Company Analysis Walmart (WMT) - Walmart has historically thrived during recessions due to its essential grocery offerings and reputation for affordability, attracting budget-conscious customers [3] - Approximately two-thirds of Walmart's inventory is produced in the U.S., providing a buffer against global trade tensions [4] - Over the past year, Walmart has achieved a 47% return, significantly outperforming the S&P 500's 10% return, with analysts optimistic about steady growth in the coming months [4] HCA Healthcare (HCA) - HCA Healthcare is the largest non-governmental hospital chain in the U.S. and has shown resilience during economic downturns, particularly in critical care sectors [5] - The company reported a remarkable growth of +236.97% and aims for a 29% market share by 2030 [5] - Cantor Fitzgerald raised its price target for HCA from $405 to $444, indicating a potential 16% upside from the stock's previous closing price [6] Waste Management (WM) - Waste Management has experienced a +135.87% growth over the past five years, as demand for waste collection and recycling services remains stable during recessions [9] - The waste management industry is projected to grow at a compound annual growth rate (CAGR) of 5.4% by 2030, driven by advancements in recycling technologies and increasing environmental awareness [10] - Recent evaluations by JPMorgan indicate optimism regarding WM's growth prospects, with a valuation of approximately 16x forward-year EV/EBITDA and a free cash flow yield of 3% [11]

Core Viewpoint - HCA Healthcare has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with stock price movements [4][6]. - HCA's earnings estimates for the fiscal year ending December 2025 are projected at $25.29 per share, reflecting a 15.2% increase from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for HCA has risen by 1.4% [8]. Institutional Investor Influence - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to significant buying or selling actions that affect stock prices [4]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - HCA's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Summary of HCA Healthcare (HCA) 2025 Conference Call Company Overview - **Company**: HCA Healthcare (HCA) - **Industry**: Healthcare Services - **Event**: 2025 Conference Call on May 13, 2025 Key Points Financial Performance - **Q1 Performance**: Strong quarter with good volume growth and improved margins, attributed to operational leveraging and effective cost management [5][9] - **Net Revenue Growth**: Net revenue per unit increased by 3%, indicating solid top-line growth [9] - **EBITDA Growth**: EBITDA grew by 11% year-over-year, with a close to 9% growth when accounting for state supplemental payment impacts [33][34] Guidance and Sustainability - **Guidance Reaffirmation**: The company reaffirmed its guidance for the year, indicating a cautious approach due to the uncertain macro environment [6][8] - **Volume Growth Guidance**: Volume growth is projected at 3% to 4%, which is higher than the previous long-term target of 2% to 3% [26][32] Regulatory and Policy Environment - **Reconciliation Bill**: The draft bill is seen as largely maintaining current state supplemental payments, which is viewed positively, although it may limit future enhancement opportunities [11][12][13] - **Enhanced Premium Tax Credits (EPTCs)**: The company is advocating for the extension of EPTCs, which are crucial for coverage and cost of living for working families [15][16] Operational Insights - **Labor Trends**: The labor environment is stable, with improvements in retention rates returning to pre-pandemic levels. The company has invested in workforce development through partnerships with nursing schools [37][38][41] - **Professional Fees**: Professional fees are growing faster than inflation, with a reported 11% increase year-over-year. The company is working to stabilize these costs [42][43] Market Dynamics - **Ambulatory Surgery Centers (ASCs)**: The ASC business is experiencing mid-single-digit net revenue growth, although there have been slight volume declines in lower acuity cases [59][60] - **Non-Hospital Assets**: The company has expanded to 2,750 sites of care, with outpatient revenue growth outpacing inpatient revenue growth [61][62] Capital Allocation and Financial Strategy - **Leverage Ratio**: The leverage ratio stands at 3.1, within the targeted range of 2.75 to 3.75, indicating a strong balance sheet [65] - **Capital Investments**: The company plans to maintain a balanced approach to capital allocation, including investments in facilities, dividends, mergers and acquisitions, and share repurchases [65][68] Future Considerations - **Impact of Federal Health Policy Changes**: The company is preparing for potential adverse impacts from federal health policy changes and tariffs, with flexibility in capital allocation plans [67][68] Additional Insights - **Market Demand**: There are no current indications of deferred care or pull-forward utilization due to economic concerns, suggesting stable demand in the first quarter [28] - **Contracting with Payers**: The company is over 90% contracted for 2025 and 75% for 2026, indicating strong relationships with payers despite ongoing negotiations [50][51][55] This summary encapsulates the key insights and data points from the HCA Healthcare conference call, providing a comprehensive overview of the company's current performance, strategic outlook, and market dynamics.